Akoya Biosciences Inc (NASDAQ: AKYA) kicked off on Tuesday, down -8.80% from the previous trading day, before settling in for the closing price of $1.25. Over the past 52 weeks, AKYA has traded in a range of $0.93-$3.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 14.10% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 28.14%. With a float of $20.81 million, this company’s outstanding shares have now reached $49.84 million.
In an organization with 205 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 61.74%, operating margin of -48.22%, and the pretax margin is -59.28%.
Akoya Biosciences Inc (AKYA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Akoya Biosciences Inc is 58.29%, while institutional ownership is 24.65%. The most recent insider transaction that took place on Jun 11 ’24, was worth 15,630. In this transaction President and CEO of this company sold 7,500 shares at a rate of $2.08, taking the stock ownership to the 224,733 shares. Before that another transaction happened on Jun 06 ’24, when Company’s President and CEO sold 7,500 for $2.01, making the entire transaction worth $15,064. This insider now owns 224,733 shares in total.
Akoya Biosciences Inc (AKYA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 28.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.07% during the next five years compared to -23.03% drop over the previous five years of trading.
Akoya Biosciences Inc (NASDAQ: AKYA) Trading Performance Indicators
Take a look at Akoya Biosciences Inc’s (AKYA) current performance indicators. Last quarter, stock had a quick ratio of 0.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Akoya Biosciences Inc (AKYA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.25 million. That was inferior than the volume of 0.64 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.96%. Additionally, its Average True Range was 0.10.
During the past 100 days, Akoya Biosciences Inc’s (AKYA) raw stochastic average was set at 8.40%, which indicates a significant decrease from 41.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.17% in the past 14 days, which was higher than the 90.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2210, while its 200-day Moving Average is $2.1815. However, in the short run, Akoya Biosciences Inc’s stock first resistance to watch stands at $1.1767. Second resistance stands at $1.2133. The third major resistance level sits at $1.2567. If the price goes on to break the first support level at $1.0967, it is likely to go to the next support level at $1.0533. Assuming the price breaks the second support level, the third support level stands at $1.0167.
Akoya Biosciences Inc (NASDAQ: AKYA) Key Stats
The company with the Market Capitalisation of 56.85 million has total of 49,875K Shares Outstanding. Its annual sales at the moment are 81,670 K in contrast with the sum of -55,370 K annual income. Company’s last quarter sales were recorded 16,640 K and last quarter income was -15,650 K.
